Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BriaCell Therapeutics Corp. (V:BCT)

Business Focus: Bio Therapeutic Drugs

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for BCT within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 11, 2022 08:00 ET
TMX Group Equity Financing Statistics - December 2021
Toronto Stock Exchange, TSX Venture Exchange
Read full article
Dec 29, 2021 20:48 ET
BriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on Nasdaq
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to announce that...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.38
--
--
Price to Sales - TTM
--
44.97
10.69
Price to Book - most recent quarter
2.93
3.81
2.52
Price to Cash Flow per share - TTM
1,685.07
23.39
13.73
Price to Free Cash Flow per share - TTM
--
53.77
28.71
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 15, 20217,612-41,559
Nov 30, 202149,17126,280
Nov 15, 202122,891-152,686
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

BriaCell Therapeutics Corp. is a clinical stage immunotherapy company. The Company is focused on developing treatments that boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors. Its lead drug candidate, Bria-IMT, is a targeted immunotherapy being developed for the treatment of advanced breast cancer. The Company is focused on conducting Phase I/IIa clinical trial of Bria-IMT in a combination study with immune checkpoint inhibitors such as the Incyte drugs retifanlimab, an anti-PD-1 antibody similar to pembrolizumab, and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). The Company is also focused on development of Bria-OTS, which is an off-the-shelf personalized immunotherapy based on a patient's HLA-type. Its other pre- clinical candidates include Bria-Pros, Bria-Lung, Bria-Mel, Bria-TILsRx and others.

See business summary

 

Twitter

Search (past week) for $BCT.CA BCT.V

  • No tweets found